EGFR and non-small cell lung carcinoma: This multicenter, retrospective cohort study aimed to evaluate the clinical outcomes of dacomitinib as a first-line treatment in patients with untreated advanced EGFR-mutant NSCLC without brain metastases.<h4>Patients and methods</h4>This retrospective analysis included 161 patients with stage IIIB/IV EGFR-mutant NSCLC without brain metastasis at baseline who received first-line dacomitinib between October 2020 and August 2023 at four Taiwanese cancer centers.